Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma. Issue 11 (17th September 2021) - Biran, Noa; Gourna Paleoudis, Elli; Feinman, Rena; Vesole, David H.; Zenreich, Joshua; Wang, Shuqi; Ahn, Jaeil; Bansal, Meena; Rowley, Scott; Donato, Michele; Pecora, Andrew L.; Richter, Joshua; et al.